United Therapeutics Corporation (UTHR) Releases Earnings Results, Beats Expectations By $1.03 EPS

United Therapeutics Corporation (UTHR) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $4.55 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $1.03. Analysts had a consensus of $3.52. The company posted revenue of $412.60 million in the period, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .

United Therapeutics Corporation opened for trading at $114.01 and hit $119.92 on the upside on Thursday, eventually ending the session at $118.99, with a gain of 5.11% or 5.79 points. The heightened volatility saw the trading volume jump to 9,55,834 shares. Company has a market cap of $5,310 M.

In a different news, on Jul 15, 2016, Martine A Rothblatt (Chairman & CEO) sold 1,292 shares at $110.24 per share price. According to the SEC, on Jun 10, 2016, Raymond Dwek (director) sold 3,000 shares at $166.28 per share price. On Jun 9, 2016, Tommy G Thompson (director) sold 2,000 shares at $115.62 per share price, according to the Form-4 filing with the securities and exchange commission.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

United Therapeutics Corporation

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.